# A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

> **NCT06322095** · PHASE2 · UNKNOWN · sponsor: **Suzhou Genhouse Bio Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Patients With Advanced Solid Tumor
- Advanced Solid Tumor With Oncogenic Driver Mutations

## Interventions

- **DRUG:** PD-1
- **DRUG:** MET inhibitor
- **DRUG:** ALK inhibitor
- **DRUG:** BRAF Inhibito
- **DRUG:** EGFR Monoclonal antibody
- **DRUG:** GH21
- **DRUG:** MEK Inhibitor

## Key facts

- **NCT ID:** NCT06322095
- **Lead sponsor:** Suzhou Genhouse Bio Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-22
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06322095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06322095, "A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06322095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*